Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99.6 USD | +0.53% | +2.15% | -1.36% |
05-06 | NOVARTIS AG : UBS maintains a Buy rating | ZD |
05-02 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's enterprise value to sales, at 4 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.36% | 202B | - | ||
+32.95% | 700B | C+ | ||
+26.51% | 569B | B | ||
-4.97% | 358B | C+ | ||
+18.83% | 330B | B- | ||
+3.54% | 287B | C+ | ||
+15.70% | 236B | B+ | ||
-9.08% | 197B | A+ | ||
+6.70% | 161B | C+ | ||
-1.81% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- NVS Stock
- Ratings Novartis AG